SURIO-001

**SURIO-001** is an investigational first-in-class targeted oncology combination developed by Surio Therapeutics using its ATTACK platform. The product combines **ST114**, an unnatural-sugar tumor-labeling reagent that metabolically installs clickable artificial receptors on cancer-cell surfaces through recognition of an overexpressed tumor-associated protein target, with **ST205**, a tubulin-inhibitor conjugate that binds those artificial receptors by click chemistry and delivers cytotoxic activity selectively to labeled tumor cells. SURIO-001 completed a Phase Ia study in healthy participants and is planned to enter Phase Ib evaluation in patients with advanced solid tumors. ([suriothera.com](https://www.suriothera.com/?list_8%2F33.html=))

Other names

ST114 + ST205SURIO 001SURIO001SURIO-001